4.0 Article

Deoxycholic Acid (ATX-101) for Fat Reduction

期刊

JOURNAL OF DRUGS IN DERMATOLOGY
卷 20, 期 11, 页码 1169-1173

出版社

JOURNAL OF DRUGS IN DERMATOLOGY
DOI: 10.36849/JDD.3936

关键词

-

向作者/读者索取更多资源

ATX-101 is the only injectable drug approved in the United States and Canada for reduction of moderate or severe submental fat in adults, with proven efficacy and safety profile. The research emphasizes careful patient selection, advises on appropriate volume administration, treatment frequency, and injection technique. Studies included peer-reviewed articles and were conducted through electronic databases and references until December 2019, focusing on English-language publications.
Excess, unwanted fat in submental and other body areas has been a focus of new modalities in aesthetics. Invasive and, more recently, non-invasive modalities for removal of unwanted fat have been on an increase. ATX-101 (deoxycholic acid injection) is the only injectable drug approved in the United States and Canada for reduction of moderate or severe submental fat in adults, with ongoing trials testing its efficacy in body contouring and lipomas. It has proven efficacy in submental fat reduction with a good safety profile. This article reviews the pharmacology, mechanism of action, clinical effects and adverse effects of ATX-101. It emphasizes on careful patient selection and advises on appropriate volume administration, number of treatments, and injection technique. The literature research includes peer-reviewed articles (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) till December 2019 and reference lists of respective articles. Only articles published in English language were included.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据